New data from the Alzstatin Alzheimer’s Project presented at the 11th Pharmaceutical Profiling Meeting


AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain , today announced that the company’s presentation and poster for the neurology research platform, Alzstatin, as presented at the 11th Symposium on Pharmaceutical Profiling in Drug Discovery and Development on January 27, 2022 in Upsala, Swedenare now available in full on the company’s website.

The poster, titled Development of new gamma-secretase modulators for the treatment of Alzheimer’s diseasewas presented by Dr. Maria Backlund and contains new preclinical data showing potent effects on amyloid production indicating that alzstatin is a promising preventative and disease-modifying therapy for the treatment of early-onset Alzheimer’s disease.

The presentation included data on the effects of AC-0027875, a potent new compound of the Alzstatin platform, on the reduction of Aβ42 in cells and animals.
AC-0027875 effectively reduced Aβ42 production in cells and lowered Aβ42 in brain in a time-dependent manner. The compound has also displayed good pharmacokinetic properties and further studies with the compound are currently underway.

“Aggregation of the toxic beta-amyloid, Aβ42, leads to the formation of amyloid plaques – a process that plays a central role in the early pathogenesis of Alzheimer’s disease. Modulators of γ-secretase, called GSM, represent a promising class of Aβ42-lowering anti-amyloidogenic compounds that differentiates itself from antibody therapies and our compounds in Alzstatin are prime examples,” said Martin Jönsson, CEO of AlzéCure Pharma.

The presentation, the poster and the summary are available on the AlzeCure website: (


Comments are closed.